Enochian Biosciences Inc

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Renovaro Biosciences Inc

LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has executed a binding, exclusive letter of intent to merge a subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.

AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

Atara Biotherapeutics

Pieris Pharma

The world of biotech stocks is notoriously difficult to predict. History is littered with companies that appeared destined for superstar status only to crash and burn.

3 Doomed Biotech Stocks Destined for Disaster

LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting

LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company's Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024.

Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Turning the Page; A Promising Future Turning the Page; A Promising Future

Enochian BioSciences' CEO Letter to Shareholders

LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company's proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act.

Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively.

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended December 31, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Company received notices from Nasdaq indicating that as a result of not having timely filed its Annual Report on Form 10-K for the period ended June 30, 2022 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the period ended September 30, 2022, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1).

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 17, 2022, the Company previously received a notice from Nasdaq indicating that as a result of not having timely filed its Annual Report on Form 10-K for the period ended June 30, 2022 (the "Form 10-K"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1).

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world's deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center.

Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K

Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer

Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform

NEW YORK , Sept. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Enochian BioSciences, Inc..

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Enochian BioSciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 26, 2022 - (NASDAQ: ENOB)

New York, New York--(Newsfile Corp. - September 26, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive, (the "Class Period"), including common stock issued by Enochian in a private placement offering on or about February 16, 2018, of the important September 26, 2022 lead plaintiff deadline.

ENOB FINAL DEADLINE TODAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action - ENOB

Los Angeles, California--(Newsfile Corp. - September 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences, Inc. ("Enochian" or "the Company") (NASDAQ: ENOB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 26, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) securities between January 17, 2018 and June 27, 2022, inclusive (the “Class Period”), including common stock issued by Enochian in a private placement offering on or about February 16, 2018. If you are a sha

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Enochian Biosciences, Inc. (ENOB)

New York, New York--(Newsfile Corp. - September 23, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Enochian Biosciences Inc.

Bronstein, Gewirtz & Grossman, LLC Reminds Enochian Biosciences Inc. (ENOB) Investors of Class Action and Encourages Investors to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences, Inc. ("Enochian" or "the Company") (NASDAQ: ENOB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 23, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Enochian BioSciences, Inc. (NASDAQ: ENOB).

ENOB SHAREHOLDER ALERT: Jakubowitz Law Reminds Enochian Shareholders of a Lead Plaintiff Deadline of September 26, 2022

New York, New York--(Newsfile Corp. - September 22, 2022) - Levi & Korsinsky, LLP notifies investors in Enochian BioSciences, Inc. ("Enochian" or the "Company") (NASDAQ: ENOB) of a class action securities lawsuit.The lawsuit on behalf of Enochian investors has been commenced in the the United States District Court for the Central District of California. Affected investors purchased or otherwise acquired certain Enochian BioSciences, Inc. securities between January 17, 2018 and June 27, 2022.

Enochian Class Action: Levi & Korsinsky Reminds Enochian BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 26, 2022 - ENOB

Los Angeles, California--(Newsfile Corp. - September 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences, Inc. ("Enochian" or "the Company") (NASDAQ: ENOB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 22, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Enochian BioSciences, Inc. ("Enochian" or the "Company") (NASDAQ: ENOB) of a class action securities lawsuit.

ENOB LAWSUIT ALERT: Levi & Korsinsky Notifies Enochian BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

BENSALEM, Pa. , Sept. 20, 2022 /PRNewswire/ -- Law Offices of Howard G.

ENOB Investors Have Opportunity to Lead Enochian Biosciences, Inc. Securities Fraud Lawsuit

NEW YORK , Sept. 20, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Enochian BioSciences, Inc. (NASDAQ: ENOB) alleging that the Company violated federal securities laws.

ENOB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 26, 2022 in the Class Action Filed on Behalf of Enochian BioSciences, Inc. Shareholders

NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Attention Enochian BioSciences, Inc. ("Enochian") (NASDAQ: ENOB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 17, 2018 and June 27, 2022.

News for Enochian Biosciences Inc Stock (ENOB)